“This represents the first Canadian regulatory approval of a product from Barrier Therapeutics' development pipeline. We anticipate launching Xolegel in Canada in the second half of this year,” said Joan Chypyha, general manager of Barrier Therapeutics Canada.
Seborrheic dermatitis is a common, recurring skin inflammation characterized by a red, scaly, itchy rash primarily on the face, scalp, hairline, eyebrows and torso.
Traditional prescription therapies for seborrheic dermatitis have previously consisted primarily of treatment options that require multiple applications per day over periods of up to four weeks to be effective.
According to Barrier Therapeutics, Xolegel provides patients with a convenient dosing regimen of a once daily application for two weeks, requiring approximately 75% fewer applications compared to some traditional therapies. Xolegel has been shown to be effective with minimal skin irritation and is steroid-free.